PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Diosmin→

Diosmin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
520-27-4
Molecular formula
C28H32O15
Molecular weight
608.5 g/mol
Drug class
Flavonoid venotonic and vasoprotective agent (often supplied in micronised purified flavonoid fraction)
Mechanism of action
Reduces venous distensibility and venous stasis, improves venous tone, decreases capillary permeability and fragility, and supports lymphatic drainage. These effects are attributed to modulation of noradrenergic signalling and inflammatory mediators; the full molecular mechanism is not completely defined.
Indications / reported uses
  • Symptomatic treatment of chronic venous disease, including heaviness, pain and swelling of the legs, where authorised
  • Short-term treatment of symptoms of acute haemorrhoidal disease in product-authorised settings

Sources: UK SmPC — Daflon 500 mg (diosmin/hesperidin) · European Medicines Agency — diosmin/flavonoid class evidence overview · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Diosmin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diosmin Permitted Daily Exposure (PDE) report (the Diosmin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diosmin Occupational Exposure Limit (OEL) report (the Diosmin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.